4.7 Article

A polyphenol-assisted IL-10 mRNA delivery system for ulcerative colitis

Journal

ACTA PHARMACEUTICA SINICA B
Volume 12, Issue 8, Pages 3367-3382

Publisher

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2022.03.025

Keywords

Polyphenol; mRNA; IL-10; Colitis; Inflammatory bowel disease; Drug delivery; mRNA delivery; Supramolecular binding

Funding

  1. Science and Technology Development Fund, Macau SAR (China) [00151/2020/A3, SKL-QRCM(UM)2020-2022]
  2. Major Basic and Applied Basic Research Projects of Guangdong Province of China [2019B030302005]
  3. Guangxi Science and Technology Research Project (China) [GuiKeAA18242040]
  4. University of Macau (China) [MYRG2020-00141-ICMS, EF013/ICMS-WYT/2019/GPU]

Ask authors/readers for more resources

With the assistance of polyphenols, a handy delivery strategy has been proposed for efficient in vivo delivery of IL-10 mRNA, showing potential for the treatment of ulcerative colitis.
With the development of synthesis technology, modified messenger RNA (mRNA) has emerged as a novel category of therapeutic agents for a broad of diseases. However, effective intracellular delivery of mRNA remains challenging, especially for its sensitivity to enzymatic degradation. Here, we propose a polyphenol-assisted handy delivery strategy for efficient in vivo delivery of IL-10 mRNA. IL-10 mRNA binds to polyphenol ellagic acid through supramolecular binding to yield a negatively charged core, followed by complexing with linear polyetherimide and coating with bilirubin-modified hyaluronic acid to obtain a layer-by-layer nanostructure. The nanostructure specifically up-regulated the level of IL-10, effectively inhibited the expression of inflammatory factors, promoted mucosal repair, protected colonic epithelial cells against apoptosis, and exerted potent therapeutic efficacy in dextran sulfate sodium salt-induced acute and chronic murine models of colitis. The designed delivery system without systemic toxicity has the potential to facilitate the development of a promising platform for mRNA delivery in ulcerative colitis treatment. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available